Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigating the Immunomodulatory Effects of Esmolol in Sepsis Management and Its Impact on Patient Outcomes

NCT06390748 is registered in ClinicalTrials.gov with Lin Chen as lead sponsor.

NCT NCT06390748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06390748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigating the Immunomodulatory Effects of Esmolol in Sepsis Management and Its Impact on Patient Outcomes
Lead sponsor
Lin Chen
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2021
Completion date
December 31, 2023
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

beta-blocker, catecholamine; overproduction, cytokine storm, immunologic paralysis, lymphocyte disorder t, sepsis, sympathetic nervous system diseases